CLYM vs STTK
CLYM: Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and lupus. STTK: Shattuck Labs is a clinical-stage biotech developing novel protein therapeutics to treat inflammatory and immune-mediated diseases by targeting the DR3/TL1A pathway.
Side-by-side fundamentals
| Metric | CLYM | STTK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $12.79 | $7.04 | |
| Market cap as of 2026-07-30 | $693M | $540M | |
| Net margin as of 2026-07-30 | n/a | -1005.6% | |
| Operating margin as of 2026-07-30 | n/a | -1071.6% | |
| ROE as of 2026-07-30 | -31.5% | -60.7% | CLYM higher |
| ROA as of 2026-07-30 | -30.4% | -55.8% | CLYM higher |
| Debt / equity as of 2026-07-30 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-30 | n/a | -78.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +15.3% | |
| Beta as of 2026-07-30 | 0.11 | 1.00 | |
| 1-year return as of 2026-07-27 close | +782.1% | +732.2% | CLYM higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.